Nanochemistry Modulates Intracellular Decomposition Routes of S‐Nitrosothiol Modified Silica‐Based Nanoparticles

Theivendran, Shevanuja; Yu, Chengzhong

doi:10.1002/smll.202007671

Cited by 12 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[126] SNO GSH-responsive NO release NO induces apoptosis in cancer cells. [131] Arg 808 nm laser-activated IR783 transfers its energy or electron to oxygen to generate ROS dominantly composed of 1 O 2 that induces release of NO from l-Arg…”

Section: Nonoatementioning

confidence: 99%

“…Yu et al prepared tetrasulfide bond-containing dendritic mesoporous SiO 2 nanoparticles, with modified SNO on the surface (DMON-SNO). [131] The tetrasulfide bridging group oxidizes the high concentration of GSH in tumor cells into oxidized glutathione (GSSG). Due to the retention of GSH by the tetrasulfide bridging group, DMON-SNO shifts the reaction to NO release and reduces NH 3 production.…”

Section: 𝛼-Cd-conjugated No Prodrug (𝛼-Cd-no) and Ce6 (𝛼-Cd-ce6mentioning

confidence: 99%

See 1 more Smart Citation

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Liu

2022

Advanced Therapeutics

View full text Add to dashboard Cite

Nitric oxide (NO) serves a multitude of functions in human physiology and pathology, and therapeutic NO-releasing materials are vigorously developed for biomedical applications. Owing to its complex functions and its potential systemic effects, controllable NO release is desired for clinical applications. This review summarizes recent developments in the last five years in designing controllable NO-delivering platforms for treating diseases such as cancer, bacterial infection, cardiovascular diseases, wounds, and eye diseases, with a focus on the most commonly used NO donors, including N-diazeniumdiolates, S-nitrosothiols, arginine, and N-nitrosoamines. The progress and success of NO delivery strategies are highlighted, and their limitations are also included. Moreover, the therapeutic mechanisms of NO in the diseases are summarized, along with the corresponding means of controlling NO release. Finally, the prospects and potential challenges regarding the development of NO gas therapy are described, with the hope of encouraging new research in this area.

show abstract

Section: Nonoatementioning

confidence: 99%

Section: 𝛼-Cd-conjugated No Prodrug (𝛼-Cd-no) and Ce6 (𝛼-Cd-ce6mentioning

confidence: 99%

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Liu

2022

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…[9,10] Immunotherapy utilizes patients' own immune systems to identify and destroy cancer cells, often with high specificity and low toxicity to eradicate primary tumors, inhibit metastasis, and prevent recurrence. [11][12][13][14][15][16] Among immunotherapy methods, artificial cancer vaccines have attracted extensive attention for their longterm immune responses, a vital factor for cancer therapy. [17,18] However, individual differences may lead to limited therapeutic effectiveness, thus limiting the clinical application of artificial cancer vaccines.…”

Section: Introductionmentioning

confidence: 99%

Selective Manipulation of the Mitochondria Oxidative Stress in Different Cells Using Intelligent Mesoporous Silica Nanoparticles to Activate On‐Demand Immunotherapy for Cancer Treatment

Chang,

Zhu,

Weng

et al. 2023

Small

View full text Add to dashboard Cite

Herein, the vitamin K2 (VK2)/maleimide (MA) coloaded mesoporous silica nanoparticles (MSNs), functional molecules including folic acid (FA)/triphenylphosphine (TPP)/tetrapotassium hexacyanoferrate trihydrate (THT), as well as CaCO3 are explored to fabricate a core‐shell‐corona nanoparticle (VMMFTTC) for on‐demand anti‐tumor immunotherapy. After application, the tumor‐specific acidic environment first decomposed CaCO3 corona, which significantly levitates the pH value of tumor tissue to convert M2 type macrophage to the antitumor M1 type. The resulting VMMFTT would then internalize in both tumor cells and macrophages via FA‐assisted endocytosis and free endocytosis, respectively. These distinct processes generate different amount of VMMFTT in above two cells followed by 1) TPP‐induced accumulation in the mitochondria, 2) THT‐mediated effective capture of various signal ions to cut off signal transmission and further inhibit glutathione (GSH) generation, 3) ions catalyzed reactive oxygen species (ROS) production through Fenton reaction, 4) sustained release of VK2 and MA to further enhance the ROS production and GSH depletion, which caused significant apoptosis of tumor cells and additional M2‐to‐M1 macrophage polarization via different processes of oxidative stress. Moreover, the primary tumor apoptosis further matures surrounding immature dendritic cells and activates T cells to continuously promote the antitumor immunotherapy.

show abstract

“…36 For example, tetrasulfide-bridged silica nanoparticles have been demonstrated to deliver cargo in GSH-rich cell types. 4,37,38 Herein, we report the repurposed application of Pio for CAF reprogramming using an organosilica-based nano-delivery platform. Dendritic mesoporous organosilica nanoparticles (DMONs) with a tetrasulfide bridging group loaded with pioglitazone (DMON-P) have been prepared.…”

mentioning

confidence: 99%

“…According to previous research, CAFs have been observed to possess increased levels of intracellular glutathione (GSH), which can be used as an intracellular cue for the responsive release of cargo . For example, tetrasulfide-bridged silica nanoparticles have been demonstrated to deliver cargo in GSH-rich cell types. ,, …”

mentioning

confidence: 99%

A Pioglitazone Nanoformulation Designed for Cancer-Associated Fibroblast Reprogramming and Cancer Treatment

Theivendran,

Xian,

et al. 2024

Nano Lett.

Self Cite

View full text Add to dashboard Cite

The recent focus of cancer therapeutics research revolves around modulating the immunosuppressive tumor microenvironment (TME) to enhance efficacy. The tumor stroma, primarily composed of cancer-associated fibroblasts (CAFs), poses significant obstacles to therapeutic penetration, influencing resistance and tumor progression. Reprogramming CAFs into an inactivated state has emerged as a promising strategy, necessitating innovative approaches. This study pioneers the design of a nanoformulation using pioglitazone, a Food and Drug Administration-approved anti-diabetic drug, to reprogram CAFs in the breast cancer TME. Glutathione (GSH)-responsive dendritic mesoporous organosilica nanoparticles loaded with pioglitazone (DMON-P) are designed for the delivery of cargo to the GSH-rich cytosol of CAFs. DMON-P facilitates pioglitazone-mediated CAF reprogramming, enhancing the penetration of doxorubicin (Dox), a therapeutic drug. Treatment with DMON-P results in the downregulation of CAF biomarkers and inhibits tumor growth through the effective delivery of Dox. This innovative approach holds promise as an alternative strategy for enhancing therapeutic outcomes in CAF-abundant tumors, particularly in breast cancer.

show abstract

Nanochemistry Modulates Intracellular Decomposition Routes of S‐Nitrosothiol Modified Silica‐Based Nanoparticles

Cited by 12 publications

References 42 publications

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Selective Manipulation of the Mitochondria Oxidative Stress in Different Cells Using Intelligent Mesoporous Silica Nanoparticles to Activate On‐Demand Immunotherapy for Cancer Treatment

A Pioglitazone Nanoformulation Designed for Cancer-Associated Fibroblast Reprogramming and Cancer Treatment

Contact Info

Product

Resources

About